Pharmaceutical application of a pi3k and mth1 targeting drug composition

A composition, the technology of MBKM120, applied in the field of medicine, can solve the problem that cell proliferation is not inhibited, and achieve the effects of improving drug sensitivity, enhancing therapeutic effect, and promoting cell proliferation.

Active Publication Date: 2020-05-29
NANJING MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the U251 cell line with activating mutations in the PI3K signaling pathway, BKM120 at a concentration of 1 μM could significantly down-regulate the expression of p-AKT, but the cell proliferation was not inhibited. For this type of glioma cells, we used targeting 178 Targeted 601 small molecule drug library, each drug in the library was combined with 1 μM BKM120, and another MTH1 small molecule targeting drug TH588, which has a synthetic lethal effect with BKM120 in the U251 cell line, was found, and the combination of the two drugs Can significantly inhibit the proliferation of U251 cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical application of a pi3k and mth1 targeting drug composition
  • Pharmaceutical application of a pi3k and mth1 targeting drug composition
  • Pharmaceutical application of a pi3k and mth1 targeting drug composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Western blot was used to detect the changes in the signaling pathways of U251, T98G, and U87 glioma cell lines under different concentrations of BKM120 monotherapy. The specific implementation plan is as follows:

[0044] 1. Press 6ⅹ10 for U251, T98G, and U87 cell lines one day in advance 5 / Dish spread in 6cm dishes, 7 dishes for each kind of cells.

[0045] 2. Prepare single-drug BKM120 at concentrations of 0.1 μM, 1 μM, 2 μM, 4 μM, 8 μM, and 10 μM.

[0046] 3. Add 5mL of the drug in step 2 to each plate 24 hours after the cells are plated, and add DMSO with a concentration of 2‰ to the control group for 24 hours.

[0047] 4. After 24 hours of drug treatment, wash the cells twice with PBS, drain, add 200 μL of cell lysate to each dish, collect the lysed cells into a 1.5mL EP tube with a scraper, and then lyse at 4°C for half an hour, 13000rpm Centrifuge for 15 min to take the supernatant and store at -80°C.

[0048] 5. Use the BCA method to measure the protein cont...

Embodiment 2

[0052] The colony formation experiment was used to detect the long-term growth of various glioma cell lines under the single drug action of BKM120. The specific implementation plan is as follows:

[0053] 1. Eight glioma cell lines U251, LN18, SNB19, U118, LN229, U87, A172, T98G were planted in a 12-well plate at an amount of 800 cells per well.

[0054] 2. Prepare BKM120 at concentrations of 500nM, 750nM and 1μM, and set up a group of blank controls with DMSO at a concentration of 2‰.

[0055] 3. After 48 hours, wait for the cells in step 1 to adhere to the wall, add 2 mL of the drug prepared in step 2 to each well, change the dressing every 3 days, and withdraw the drug for 3 days after continuous culture for 14 days.

[0056] 4. Remove the medium 3 days after drug withdrawal, wash twice with PBS, wash once with deionized water, fix with 4% paraformaldehyde for 15 minutes, wash once with deionized water, stain with 1× Giemsa stain in the dark for 30 minutes, wash with deionize...

Embodiment 3

[0059] Alamar blue was used to detect the cell proliferation of BKM120, TH588 single drug and two drugs in combination, and the SI value was calculated. The specific implementation plan is as follows:

[0060] 1. The day before, U251 and SNB19 were seeded in 96-well plates at 1000 cells per well; LN229, A72, LN18, U118MG, and T98G were planted in 96-well plates at 2000 cells per well. 3 replicate wells, and set up a control group.

[0061] 2. Prepare single-drug BKM120 100nM, BKM120 1μM, TH588 10μM, TH588 2μM; double-drug BKM120 100nM+TH588 10μM, BKM120 100nM+TH588 2μM, BKM120 1μM+TH588 10μM, 1KM28+TH.

[0062] 3. After the cells adhere to the wall in step 1, the old medium is discarded, and then 100 μL of the mixture of complete medium and 10 μL of Lamar Blue is added to each well. After incubation in a cell culture incubator with 5% carbon dioxide at 37°C for 4 hours, use a chemiluminescence instrument to Under the conditions of excitation light wavelength 534nm and emissio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a PI3K and MTH1 targeting drug composition and applications thereof. The small-molecule targeting drug composition and a drug preparation provided by the invention comprise afirst preparation formed by a PI3K inhibitor or a pharmaceutically-acceptable carrier thereof, and a second preparation formed by a MTH1 inhibitor or a pharmaceutically-acceptable carrier thereof. Thecompatibility is reasonable. The combination of the two preparations can improve the drug sensitivity of the PI3K inhibitor, play the role of the MTH1 small-molecule inhibitor in the anti-tumor aspect and increase the treatment effect of the PI3K inhibitor. Experiments prove that: the combined administration of the PI3K inhibitor and the MTH1 inhibitor obviously enhances the tumor cell activity inhibition compared with the single administration, reduces the single administration dosage, can reduce the drug toxicity, is expected to become a new tumor treatment scheme aiming at the non-ideal treatment effect of the PI3K inhibitor, and has wide application prospect.

Description

technical field [0001] The present invention belongs to the field of medical technology, and in particular relates to the application of two PI3K small molecule inhibitors BKM120 and GDC0941 and two MTH1 small molecule inhibitors TH588 and TH287 combined drugs in inhibiting the growth of tumor cells, especially in the preparation of inhibitors of brain glial Application in tumor and lung cancer cell growth drugs. Background technique [0002] With the rapid development of human society and economy, the incidence of malignant tumors is also increasing, seriously threatening human life and health, and causing a heavy burden to society and families. Therefore, to explore the pathogenesis of malignant tumors and find effective therapeutic targets Points and therapeutic drugs are of great significance. According to the 2018 cancer statistics report, the estimated new incidence of malignant tumors in the country is 3.804 million cases (2.114 million cases in men and 1.690 million...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61P35/00
CPCA61K45/06A61P35/00
Inventor 林凡周婷婷陈真
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap